NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

NEW YORK – UniQure on Monday said it will begin treating a second cohort of Fabry disease patients with a higher dose of its AMT-191 gene therapy in a Phase I/IIa trial. The decision to advance the ...

The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

Thirty patients have received the gene therapy within a clinical trial and early-access program, and the foundation also hopes to seek approval in the US.